Celecoxib inhibition of hepatic IRI for both COX-2^−M/−M mice and COX-2^+/+ mice.

<p>Liver H&E staining (panel A) demonstrated that administration of celecoxib, a selective COX-2 inhibitor, markedly reduced hepatocellular necrosis and vascular congestion in both COX-2^+/+ mice (c) and COX-2^−M/−M mice (d), when compared with respective vehicle treated COX-2^+/+ mice (a) and COX-2^−M/−M mice (b) controls 6 h post IRI. Celecoxib therapy significantly reduced the serum AST (panel B) and ALT (panel C) levels in both COX-2^+/+ mice (dark grey bars) and COX-2^−M/−M mice (light grey bars), when compared to respective vehicle treated control COX-2^+/+ mice (black bars) and COX-2^−M/−M mice (white bars) after 6 h of hepatic IRI (n = 5/group; * indicates p<0.05).